Bioequivalence trial of diclofenac: effects of Eudragit and tablet preparation, formulation characterization, release profiles, and bioavailability measurements

Sanja Kecman

doi:10.5937/pomc15-16350

Sanja Kecman Hemofarm d.o.o. Banjaluka

DOI: https://doi.org/10.5937/pomc15-16350

Sažetak

Abstract

The study aimed to evaluate the effects of changing excipients including type of Eudragit polymer, on release and absorption profiles in vitro and in vivo, of tablets containing the antiinflammatory drug, diclofenac. Formulation 1 consisted of diclofenac tablets containing Eudragit L30, and Formulation 2 consisted of diclofenac tablets containing Eudragit L100, and both formulations contained different excipients. Tablets were assessed, in vitro, for weight, hardness, diameter, thickness, mass uniformity, disintegration and dissolution profiles and drug content. Tablets were also assessed in vivo by gavage in healthy rabbits and assessing diclofenac plasma concentrations and pharmacokinetic parameters. Results showed that in vitro analyses demonstrated non-equivalence while in vivo analyses demonstrated equivalence. This suggests that although different types of Eudragit and excipients modulated the in vitro dissolution and release profiles of diclofenac, in vivo absorption in rabbits remained similar representing bioequivalence.

Reference

. J. Popovic, M. Mikov, A. Sabo, V. Jakovljevic, Evaluation of statistical power function for various diclofenac bioequivalence trials with different subject numbers, European Journal of Drug Metabolism and Pharmacokinetics 34(2) (2009) 85-91.

. H. Ali, M.H. Shoaib, F. Zafar, M. Hanif, R. Bushra, A. Naz, R. Khursheed, Pharmacokinetic and bioequivalence studies of immediate release diclofenac potassium tablets (50mg) in healthy volunteers, Pak J Pharm Sci 29(5) (2016) 1671-1679.

. In-vitro/In-vivo Correlation for Extended-Release Oral Dosage Forms. Stimuli to the Revision Process. The United States Pharmacopeia Convention Inc 1988; 4160.

. PMA's Joint Committee on Bioavailability. The Role of Dissolution Testing in Drug Quality, Bioavailability and Bioequivalence Testing.Pharm. Technol 1985; 9:62-66

. Welling PG.Pharmacokinetics, Processes and Mathematics.American Chemical Society. Washington. D.C. 1986;35-76.

. Selen A. Factors Influencing Bioavailability and Bioequivalence, in Pharmaceutical Bioequivalence.Welling PG, Tse FLS and Dighe SV. Marcel Dekker Inc New York 1991;117-148.

. Food and Drug Administration (FDA). Guidance for industry: dissolution testing of immediate release solid oral dosage forms.Center for drug evaluation and research 1997.

. Basmenji S, Valizadeh H, Zakeri-Milani P. Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. Arzneimittelforschung 2011;61(10):566-570.

.Iqbal Z1, Khan R, Nasir F, Khan JA, Rashid A, Khan A, Khan A. Preparation and in-vitro in-vivo evaluation of sustained release matrix diclofenac sodium tablets using PVP-K90and natural gums. Pakistan JPharmSci 2011 Oct;24(4):435-43.

. Emara LH, Taha NF, El-Ashmawy AA, Raslan HM, Mursi NM. Controlled porosity osmotic pump system for the delivery of diclofenac sodium: in-vitro and in-vivo evaluation.Pharm Dev and Technol2014; 19(6):681-91. DOI: 10.3109/10837450.2013.823990.

. Hosny EA, El-Mahrouk GM, Gouda MW. Formulation and In Vitro and In Vivo Availability of Diclofenac Sodium Enteric-Coated Beads. Drug Dev Ind Pharm 1998; 24(7): 661-6.

. Su SF, Chou CH, Kung CF, Huang JD. In vitro and In vivo comparison of two diclofenac sodium sustained release oral formulations. Int J Pharma 2003; 260:39-46.

. Guidance for Industry Q2(R1). Validation of Analitical Procedures, November 2005 ICH

. Guidance for Industry. Analitical procedures and Methods Validation. FDA -CDER-CBER, February 2014

. Center of Drug Evaluation and Research-Rewiewe. Guidance Validation of Chromatographic Methods. November 1996

. European Pharmacopeia. 8th Edition, 2016.

. Westlake, W.J. Bioavailability and Bioequivalence of Pharmaceutical Formulations, in Biopharmaceutical Statistics for Drug Development.Peace, K.E., ed., Marcel Dekker, Inc., New York 1988; 329-352.

. Lehmann K, Dreher D. Mixtures of Aqueous Polymethacrylate Dispersions for Drug Coating, Drugs Made Ger 1988; 31: 101-102.

. Emami J, Ghassami N, Talari R. A rapid and sensitive modified HPLC method for determination of diclofenac in human plasma and its application in pharmacokinetic studies. DARU Journal of Faculty of Pharmacy,2007; 15(3):132-8.

. Shargel L. and Yu ABC.Applied Biopharmaceutics and Pharmacokinetics, Appleton & Lange.Norwalk, Connecticut, 1993;111-167.

. De CastroWV, PiresMAS, Oliveira MA, Vianna-Soares CD, NunanmEA, Pinetti GA. The influence of Formulation on the Dissolution Profile of Diclofenac Sodium Tablets.Drug Dev Ind Pharm. 2006; 32:1103-1109.